Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:1564-1570
doi: 10.1161/hc3801.096395
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Exner, D. V.
Right arrow Articles by Prystowsky, E. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Exner, D. V.
Right arrow Articles by Prystowsky, E. N.
Related Collections
Right arrow Primary prevention

(Circulation. 2001;104:1564.)
© 2001 American Heart Association, Inc.


Clinical Cardiology: New Frontiers

Primary Prevention of Sudden Death With Implantable Defibrillator Therapy in Patients With Cardiac Disease

Can We Afford to Do It? (Can We Afford Not To?)

Derek V. Exner, MD, MPH; George J. Klein, MD; Eric N. Prystowsky, MD

From the Cardiovascular Research Group, University of Calgary, Calgary, Canada (D.V.E.); the Division of Cardiology, University of Western Ontario, London, Canada (G.J.K.); and Clinical Electrophysiology Laboratory, Northside Cardiology, St Vincent Hospital, Indianapolis, Ind (E.N.P.).

Correspondence to Derek V. Exner, MD, 3330 Hospital Dr NW, Room G208, Calgary, AB, Canada T2N 4N1. E-mail exner@ucalgary.ca


Key Words: cardiac arrest • cost-effectiveness • heart failure • myocardial infarction • prevention


*    Introduction
 
Sudden cardiac death (SCD) is a major public health problem in North America, responsible for approximately 400 000 deaths annually.1,2 Most episodes of SCD in ambulatory populations result from ventricular tachyarrhythmias,3 whereas bradyarrhythmias may be important in some populations, notably hospitalized patients with advanced heart failure4 (Figure 1). A prior article in this series by Zipes and Wellens2 provides a detailed review of the pathogenesis of SCD, its underlying causes, and treatment strategies.


Figure Removed (Available Only in the Full Text)
View larger version (24K):
[in this window]
[in a new window]
 
Figure 1. Mechanisms of SCD in ambulatory persons. Most SCDs result from ventricular fibrillation. VT, bradyarrhythmias, and other mechanisms account for the remainder.

ICD Therapy
The availability of a therapy that reliably terminates the vast majority of life-threatening tachyarrhythmic and bradyarrhythmic events has tremendous clinical appeal. The implantable cardioverter defibrillator (ICD) represents such a therapy. Despite its appeal, the ICD is imperfect. Currently, systems are costly, have a limited life expectancy, and are subject to complications in the long term.5,6 Furthermore, many patients at risk for SCD are at risk of dying from causes that the ICD would not alter. The impact of ICD shocks also merits consideration. Evidence links multiple shocks with myocardial injury7 and fibrosis,8 and sporadic shocks are associated with significant, independent reductions in quality of life. Compared with patients not having shocks, patients in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial who had >=1 shocks in the initial year of follow-up had significant declines in self-perceived physical functioning and mental well-being, independent of ejection fraction (EF), social circumstances, and medication use. The reduction . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346.
[Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 746 - 837.
[Full Text] [PDF]


Home page
ChestHome page
E. G. Manios, E. M. Kallergis, E. M. Kanoupakis, H. E. Mavrakis, D. C. Kambouraki, D. A. Arfanakis, and P. E. Vardas
Amino-Terminal Pro-Brain Natriuretic Peptide Predicts Ventricular Arrhythmogenesis in Patients With Ischemic Cardiomyopathy and Implantable Cardioverter-Defibrillators
Chest, October 1, 2005; 128(4): 2604 - 2610.
[Abstract] [Full Text] [PDF]


Home page
J Intensive Care MedHome page
E. S. Antezano and M. Hong
Sudden Cardiac Death
J Intensive Care Med, November 1, 2003; 18(6): 313 - 329.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. E. Gutstein, S. B. Danik, J. B. Sereysky, G. E. Morley, and G. I. Fishman
Subdiaphragmatic murine electrophysiological studies: sequential determination of ventricular refractoriness and arrhythmia induction
Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1091 - H1096.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
G. Boriani, M. Biffi, C. Martignani, C. Camanini, F. Grigioni, C. Rapezzi, and A. Branzi
Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs
Eur J Heart Fail, August 1, 2003; 5(4): 419 - 425.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. S. Lee, L. D. Green, P. P. Liu, P. Dorian, D. M. Newman, F. C. Grant, J. V. Tu, and D. A. Alter
Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A Meta-Analysis
J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1573 - 1582.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. A. Mangi, T. J. Boeve, G. J. Vlahakes, C. W. Akins, A. D. Hilgenberg, J. N. Ruskin, B. M. McGovern, and D. F. Torchiana
Surgical coronary revascularization and antiarrhythmic therapy in survivors of out-of-hospital cardiac arrest
Ann. Thorac. Surg., November 1, 2002; 74(5): 1510 - 1516.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M.J.P. Raatikainen and H.V. Huikuri
Management of atrial fibrillation in patients with implantable cardioverter defibrillator. Do all need a dual chamber device?
Eur. Heart J., September 2, 2002; 23(18): 1412 - 1414.
[Full Text] [PDF]


Home page
CirculationHome page
D. J. Callans
Management of the Patient Who Has Been Resuscitated From Sudden Cardiac Death
Circulation, June 11, 2002; 105(23): 2704 - 2707.
[Full Text] [PDF]